Metabolic Modulation of Acute Myocardial Infarction
Authors:
- Rafael DíazRDRafael Díaz
- Ernesto A. PaolassoEPErnesto A. Paolasso
- Leopoldo S. PiegasLPLeopoldo S. Piegas
- Carlos D. TajerCTCarlos D. Tajer
- Manuel Gil MorenoMMManuel Gil Moreno
- Ramón CorvalánRCRamón Corvalán
- Jesús E. IseaJIJesús E. Isea
- Graciela RomeroGRGraciela Romero
- (Estudios Cardiológicos Latinoamérica) Collaborative Group(G(Estudios Cardiológicos Latinoamérica) Collaborative Group
- 24 November 1998
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 98 (21) , 2227-2234
Abstract
Background —Several trials have been performed in the past using glucose, insulin, and potassium infusion (GIK) for the treatment of acute myocardial infarction (AMI). Because of continuing uncertainty about the potential role of this therapeutic intervention, we conducted a randomized trial to evaluate the impact of a GIK solution during the first hours of AMI. Methods and Results —Four hundred seven patients with suspected AMI admitted within 24 hours of symptoms onset were enrolled. In a ratio of 2:1, 268 patients were allocated to receive GIK (high- or low-dose) and 139 to receive control. Phlebitis and serum changes in the plasma concentration of glucose or potassium were observed more often with GIK. A trend toward a nonsignificant reduction in major and minor in-hospital events was observed in patients allocated to GIK. In 252 patients (61.9%) treated with reperfusion strategies, a statistically significant reduction in mortality (relative risk [RR] 0.34; 95% CI: 0.15 to 0.78; 2 P =0.008) and a consistent trend toward fewer in-hospital events in the GIK group were observed. Conclusions —Our results confirm that a metabolic modulation strategy in the first hours of an AMI is feasible, applicable worldwide, and has mild side effects. The statistically significant mortality reduction in patients who underwent a reperfusion strategy might have important implications for the management of AMI patients. It is now essential to perform a large-scale trial to reliably determine the magnitude of benefit.Keywords
This publication has 21 references indexed in Scilit:
- Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at 1 yearJACC, 1995
- Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsThe Lancet, 1994
- Effects of glucose and fatty acids on myocardial ischaemia and arrhythmiasThe Lancet, 1994
- Randomised trial of late thrombolysis in patients with suspected acute myocardial infarctionThe Lancet, 1993
- Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarctionJACC, 1993
- RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2The Lancet, 1988
- Prevalence of Total Coronary Occlusion during the Early Hours of Transmural Myocardial InfarctionNew England Journal of Medicine, 1980
- RELATION BETWEEN SERUM-FREE-FATTY-ACIDS AND ARRHYTHMIAS AND DEATH AFTER ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1968
- Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarctionThe American Journal of Cardiology, 1962
- Cardiac Infarction and the Glucose-tolerance TestBMJ, 1962